Thoughts?-To The Moon - Tiger Brokers Online Investing Community - To The Moon

2
Comment
Favorite

Jabba93
2023-07-14

Thoughts?

Nvidia Just Confirmed an Emerging AI Boom in Biotech

Trillion-dollar AI chipmaker Nvidia just announced a huge new partnership with biotech AI startup Recursion Pharmaceuticals.AI’s application in the field of biology holds the potential to unlock enormous economic value for one simple reason: data.The drug discovery and development process is prohibitively long and expensive, but AI can significantly shorten and cheapen this process. It can map out human genetic data, identify mutations, and run simulations of compounds to fight those mutations – all in an instant.Earlier this year, Japanese pharma giant Takeda Pharmaceutical bought an experimental psoriasis drug for $4 billion – a drug that was created in only six months by using AI. And it isn’t alone.Editor’s note: “Nvidia Just Confirmed an Emerging AI Boom in Biotech” was previously published in June 2023. It has since been updated to include the most relevant information available.And Nvidia , the world’s preeminent AI company, may have just confirmed that sentiment yesterday.Nvidi

Nvidia Just Confirmed an Emerging AI Boom in Biotech

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

2

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":197724070649904,"tweetId":"197724070649904","gmtCreate":1689306876436,"gmtModify":1689306892049,"author":{"id":4141446122624682,"idStr":"4141446122624682","authorId":4141446122624682,"authorIdStr":"4141446122624682","name":"Jabba93","avatar":"https://community-static.tradeup.com/news/0c6ce3d9c54ff7e2e41c16f49736abb7","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>Thoughts?</p></body></html>","htmlText":"<html><head></head><body><p>Thoughts?</p></body></html>","text":"Thoughts?","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/197724070649904","repostId":2351473468,"repostType":2,"repost":{"id":"2351473468","pubTimestamp":1689298032,"share":"https://www.laohu8.com/m/news/2351473468?lang=&edition=full","pubTime":"2023-07-14 09:27","market":"us","language":"en","title":"Nvidia Just Confirmed an Emerging AI Boom in Biotech","url":"https://stock-news.laohu8.com/highlight/detail?id=2351473468","media":"InvestorPlace","summary":"Trillion-dollar AI chipmaker Nvidia just announced a huge new partnership with biotech AI startup Recursion Pharmaceuticals.AI’s application in the field of biology holds the potential to unlock enormous economic value for one simple reason: data.The drug discovery and development process is prohibitively long and expensive, but AI can significantly shorten and cheapen this process. It can map out human genetic data, identify mutations, and run simulations of compounds to fight those mutations – all in an instant.Earlier this year, Japanese pharma giant Takeda Pharmaceutical bought an experimental psoriasis drug for $4 billion – a drug that was created in only six months by using AI. And it isn’t alone.Editor’s note: “Nvidia Just Confirmed an Emerging AI Boom in Biotech” was previously published in June 2023. It has since been updated to include the most relevant information available.And Nvidia , the world’s preeminent AI company, may have just confirmed that sentiment yesterday.Nvidi","content":"<html><head></head><body><ul><li><p>Trillion-dollar AI chipmaker Nvidia just announced a huge new partnership with biotech AI startup Recursion Pharmaceuticals.</p></li><li><p>AI’s application in the field of biology holds the potential to unlock enormous economic value for one simple reason: data.</p></li><li><p>The drug discovery and development process is prohibitively long and expensive, but AI can significantly shorten and cheapen this process. It can map out human genetic data, identify mutations, and run simulations of compounds to fight those mutations – all in an instant.</p></li><li><p>Earlier this year, Japanese pharma giant Takeda Pharmaceutical bought an experimental psoriasis drug for $4 billion – a drug that was created in only six months by using AI. And it isn’t alone.</p></li></ul><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/08fc2b90236392ee42dd7f0689243624\" tg-width=\"768\" tg-height=\"432\"/></p><p>Source: shutterstock.com/cono0430</p><p><em>Editor’s note: “Nvidia Just Confirmed an Emerging AI Boom in Biotech” was previously published in June 2023. It has since been updated to include the most relevant information available.</em></p><p>We’ve long said that artificial intelligence (AI) will have the most profound economic impact in the medical industry, where it can be used to accelerate and cheapen everything from drug discovery to patient treatment.</p><p>And <strong>Nvidia</strong> (<strong><u>NVDA</u></strong>), the world’s preeminent AI company, may have just confirmed that sentiment yesterday.</p><p>The trillion-dollar AI chipmaker announced a huge new partnership with biotech AI startup <strong>Recursion Pharmaceuticals</strong> (<strong><u>RXRX</u></strong>), which has developed a novel AI-driven platform for drug development and discovery.</p><p>Recursion will train its AI models on Nvidia’s cloud platform, which Nvidia will then license through its newly announced BioNeMo generative AI cloud service for drug discovery.</p><p>Nvidia will also pour $50 million into Recursion in exchange for a ~4% stake in the company.</p><p>This is a massive deal. Look no further than the 78% jump in RXRX stock yesterday after the news was announced.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/302f267f96ba1037d17616e58786246c\" tg-width=\"1033\" tg-height=\"651\"/></p><p><strong><em><u>But this is likely just the start of the big boom at the convergence of AI and medicine.</u></em></strong></p><p>Nvidia is a trillion-dollar juggernaut in the world of AI. It could’ve chosen any industry to commit its money and resources to. And of all industries, it chose biotechnology.</p><p>Why?</p><p><strong>Data.</strong></p><h2 id=\"id_2063034441\">In a World of Data, Today’s AI Is Just the Beginning</h2><p>Like computers, humans are nothing more than a bunch of data strung together. </p><p>At their core, computers are just a bunch of 1s and 0s coded in sequence, with each number corresponding to a certain action for the computer to perform. Human DNA is much the same. We’re just a bunch of As, Gs, Cs, and Ts strung together. Those are the four base types found in human DNA molecules, each determining a person’s characteristics, traits, and even actions. </p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8dabc8a2a3b96cd7936b0f4eb80e9f4c\" tg-width=\"1165\" tg-height=\"435\"/></p><p>Essentially, the connecting element here is data. </p><p>That means AI can have an <strong><em>especially profound impact on the human body. </em></strong></p><p>After all, at the end of the day, what is AI? It is just a machine learning algorithm processing tons of data to learn how to perform a certain task or variety of tasks. It’s all just algorithms and data, with data acting as the model’s “fuel.”</p><p>The quantity and quality of data an AI model has access to determines the quality of the model itself. </p><p>When it comes to the human body, there is no dearth of quality data. As mentioned above, we are nothing more than a bunch of quality genetic data strung together.</p><p><strong>Apply AI to all that data, and you will change the world. </strong></p><p>Seriously. </p><p>Consider the value proposition of Recursion’s core AI technology.</p><p>Currently, it takes about $900 million and 13.5 years to develop a new successful drug. With AI constantly running simulations, drug development could happen in months and for less than $100 million.</p><p>That may sound hard to believe, but it’s true. <em>Drugs are already being discovered by AI that quickly.</em></p><h2 id=\"id_2050184267\">AI Meets Biotech</h2><p>Earlier this year, Japanese pharma giant <strong>Takeda Pharmaceutical</strong> bought an experimental psoriasis drug for $4 billion – a drug that was created in only six months by using artificial intelligence. </p><p>And it isn’t alone. </p><p>Other pharma giants like <strong>Bayer </strong>(<strong><u>BAYRY</u></strong>), <strong>Roche </strong>(<strong><u>RHHBY</u></strong>), <strong><a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> </strong>(<strong><u>SNY</u></strong>), and <strong>AstraZeneca </strong>(<strong><u>AZN</u></strong>) are actively using AI technology for drug discovery purposes. </p><p>The future of drug discovery starts now. </p><p><strong>This is big business. </strong></p><p>Research firm Deep Pharma Intelligence estimates that investments in the field of AI-powered drug discovery have tripled over the past four years to nearly $25 billion. Morgan Stanley believes that AI-powered drug discovery will lead to an additional 50 novel therapies being brought to market over the next decade, with annual sales in excess of $50 billion!</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5ee494fcf0431e3c1d2f995cb8e32fad\" tg-width=\"1174\" tg-height=\"594\"/></p><p>Source: Deep Pharma Intelligence</p><p>In other words, a $50 billion drug discovery revolution starts now. </p><p>Is your portfolio positioned for it?</p></body></html>","source":"investorplace_stock_picks","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nvidia Just Confirmed an Emerging AI Boom in Biotech</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNvidia Just Confirmed an Emerging AI Boom in Biotech\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-07-14 09:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/hypergrowthinvesting/2023/07/ai-meets-biotech-transforming-the-drug-development-process/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Trillion-dollar AI chipmaker Nvidia just announced a huge new partnership with biotech AI startup Recursion Pharmaceuticals.AI’s application in the field of biology holds the potential to unlock ...</p>\n\n<a href=\"https://investorplace.com/hypergrowthinvesting/2023/07/ai-meets-biotech-transforming-the-drug-development-process/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","BK4534":"瑞士信贷持仓","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0127658192.USD":"EASTSPRING INVESTMENTS GLOBAL TECHNOLOGY \"A\" (USD) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1316542783.SGD":"Janus Henderson Horizon Global Technology Leaders A2 SGD","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","BK4527":"明星科技股","BK4543":"AI","NVDA":"英伟达","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU1429558221.USD":"Natixis Loomis Sayles US Growth Equity RA USD","RHHBY":"罗氏控股","BAYRY":"Bayer A.G.","BK4532":"文艺复兴科技持仓","IE00BJJMRX11.SGD":"Janus Henderson Balanced A Acc SGD","BK4579":"人工智能","LU1435385759.SGD":"Natixis Loomis Sayles US Growth Equity RA SGD-H","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0642271901.SGD":"Janus Henderson Horizon Global Technology Leaders A2 SGD-H","BK4588":"碎股","LU0079474960.USD":"联博美国增长基金A","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","BK4503":"景林资产持仓","LU0889565833.HKD":"FRANKLIN TECHNOLOGY \"A\" (HKD) ACC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU0056508442.USD":"贝莱德世界科技基金A2","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","IE00BJJMRY28.SGD":"Janus Henderson Balanced A Inc SGD","AZN":"阿斯利康","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4581":"高盛持仓","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU0109392836.USD":"富兰克林科技股A","IE00BD6J9T35.USD":"NEUBERGER BERMAN NEXT GENERATION MOBILITY \"A\" (USD) ACC","BK4549":"软银资本持仓","IE0004445015.USD":"JANUS HENDERSON BALANCED \"A2\" (USD) ACC","BK4548":"巴美列捷福持仓","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","SNY":"赛诺菲安万特","RXRX":"Recursion Pharmaceuticals, Inc.","LU0097036916.USD":"贝莱德美国增长A2 USD","BK4539":"次新股","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","BK4554":"元宇宙及AR概念","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC"},"source_url":"https://investorplace.com/hypergrowthinvesting/2023/07/ai-meets-biotech-transforming-the-drug-development-process/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2351473468","content_text":"Trillion-dollar AI chipmaker Nvidia just announced a huge new partnership with biotech AI startup Recursion Pharmaceuticals.AI’s application in the field of biology holds the potential to unlock enormous economic value for one simple reason: data.The drug discovery and development process is prohibitively long and expensive, but AI can significantly shorten and cheapen this process. It can map out human genetic data, identify mutations, and run simulations of compounds to fight those mutations – all in an instant.Earlier this year, Japanese pharma giant Takeda Pharmaceutical bought an experimental psoriasis drug for $4 billion – a drug that was created in only six months by using AI. And it isn’t alone.Source: shutterstock.com/cono0430Editor’s note: “Nvidia Just Confirmed an Emerging AI Boom in Biotech” was previously published in June 2023. It has since been updated to include the most relevant information available.We’ve long said that artificial intelligence (AI) will have the most profound economic impact in the medical industry, where it can be used to accelerate and cheapen everything from drug discovery to patient treatment.And Nvidia (NVDA), the world’s preeminent AI company, may have just confirmed that sentiment yesterday.The trillion-dollar AI chipmaker announced a huge new partnership with biotech AI startup Recursion Pharmaceuticals (RXRX), which has developed a novel AI-driven platform for drug development and discovery.Recursion will train its AI models on Nvidia’s cloud platform, which Nvidia will then license through its newly announced BioNeMo generative AI cloud service for drug discovery.Nvidia will also pour $50 million into Recursion in exchange for a ~4% stake in the company.This is a massive deal. Look no further than the 78% jump in RXRX stock yesterday after the news was announced.But this is likely just the start of the big boom at the convergence of AI and medicine.Nvidia is a trillion-dollar juggernaut in the world of AI. It could’ve chosen any industry to commit its money and resources to. And of all industries, it chose biotechnology.Why?Data.In a World of Data, Today’s AI Is Just the BeginningLike computers, humans are nothing more than a bunch of data strung together. At their core, computers are just a bunch of 1s and 0s coded in sequence, with each number corresponding to a certain action for the computer to perform. Human DNA is much the same. We’re just a bunch of As, Gs, Cs, and Ts strung together. Those are the four base types found in human DNA molecules, each determining a person’s characteristics, traits, and even actions. Essentially, the connecting element here is data. That means AI can have an especially profound impact on the human body. After all, at the end of the day, what is AI? It is just a machine learning algorithm processing tons of data to learn how to perform a certain task or variety of tasks. It’s all just algorithms and data, with data acting as the model’s “fuel.”The quantity and quality of data an AI model has access to determines the quality of the model itself. When it comes to the human body, there is no dearth of quality data. As mentioned above, we are nothing more than a bunch of quality genetic data strung together.Apply AI to all that data, and you will change the world. Seriously. Consider the value proposition of Recursion’s core AI technology.Currently, it takes about $900 million and 13.5 years to develop a new successful drug. With AI constantly running simulations, drug development could happen in months and for less than $100 million.That may sound hard to believe, but it’s true. Drugs are already being discovered by AI that quickly.AI Meets BiotechEarlier this year, Japanese pharma giant Takeda Pharmaceutical bought an experimental psoriasis drug for $4 billion – a drug that was created in only six months by using artificial intelligence. And it isn’t alone. Other pharma giants like Bayer (BAYRY), Roche (RHHBY), Sanofi (SNY), and AstraZeneca (AZN) are actively using AI technology for drug discovery purposes. The future of drug discovery starts now. This is big business. Research firm Deep Pharma Intelligence estimates that investments in the field of AI-powered drug discovery have tripled over the past four years to nearly $25 billion. Morgan Stanley believes that AI-powered drug discovery will lead to an additional 50 novel therapies being brought to market over the next decade, with annual sales in excess of $50 billion!Source: Deep Pharma IntelligenceIn other words, a $50 billion drug discovery revolution starts now. Is your portfolio positioned for it?","news_type":1},"isVote":1,"tweetType":1,"viewCount":134,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":9,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}